News preview — no account needed

Science Corp. Announces European Commercial Launch of PRIMA, the Only Treatment to Restore Functional Central Vision to Patients with Geographic Atrophy Caused by Age-Related Macular Degeneration, a Leading Cause of Blindness

www.businesswire.com · July 22, 2026

Preview

Science Corporation received CE mark under the EU Medical Device Regulation from DEKRA and launched commercial availability of its PRIMA subretinal photovoltaic BCI implant across 30 European countries. Clinical trials showed 80% of patients achieved…

The complete summary, “why it matters” analysis and the original source link are available to members.

BCINeural ImplantVisionClinical Trial